

Guide to the MoCha Solid Tumors and Multiple Myeloma Biomarker Report




1. Relevant Findings

This table lists key cancer <u>genes</u> tested for. If a gene tested for was found, the description and location of any gene <u>mutations</u> are included.




2. Relevant Biomarkers

This table lists therapies (treatments) based on the cancer type and specific <u>biomarkers</u> found in the tumor. The list includes therapies for a specific cancer type as well as for other types of cancers that have the same biomarkers. Different cancer types that share biomarkers may respond to the same biomarker-targeted therapies.



3. Variant Details


The <u>biomarker</u> report lists <u>genes</u> that are known to be related to cancer in some way. It also lists changes (<u>variants</u>) in those genes found in the tumor. Doctors may find this information useful when recommending treatment. There are still some changes in cancer genes that are not understood yet. They may be included in the report if they were detected, since they have been found in many cancers. This is another reason why research on these biomarkers is important.



4. Relevant Therapy Summary

The Food and Drug and Administration (FDA) and National Comprehensive Cancer Network (NCCN) publish therapy guidelines for specific cancer types. This table lists their recommended therapies based on the <u>biomarkers</u> found in the tumor. The table also shows whether there may be clinical trials available. A clinical trial is a type of research study that tests potential new therapies.





5. Clinical Trials Summary

This table lists clinical trials that may be available for a specific type of cancer, based on gene <u>mutations</u> and or <u>biomarkers</u> found in the tumor. A clinical trial is a type of research study that tests potential new therapies.

More information on each clinical trial, such as where the clinical trial is being done, can be found at <u>ClinicalTrials.gov</u>.

	Recombination (HR) Mutation / Alteration	
NCT04383938	Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies	1/
NCT03718091	A Phase II Study of M6620 (VX-970) in Selected Solid Tumors	II
NCT02029001	A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally advanced or Metastatic Solid Tumors MOST: My own specific treatment	п
NCT03297606	Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial	11
NCT02401347	A Phase II Clinical Trial of the PARP Inhibitor Talazoparib in BRCA1 and BRCA2 Wild Type Patients With Advanced Triple Negative Breast Cancer and Homologous Recombination Deficiency or Advanced HER2 Negative Breast Cancer or Other Solid Tumors With a Mutation in Homologous Recombination Pathway Genes Talazoparib Beyond BRCA (TBB) Trial	II
NCT03415659	A Phase I, Open-label, Single-center, Single/Multiple-dose, Dose-escalation/Dose-expansion Clinical Study on Tolerance and Pharmacokinetics of HWH340 Tablet in Patients With Advanced Solid Turnors	1

Assay Information



Methodology, Scope, and Application: The OCAv3 next-generation sequencing (NGS) assay identifies more than 3000 annotated mutations of interest (MOIs) broadly categorized into 5 mutation types: single nucleotide variants (SNVs), small insertions/deletions (Indels), large (>3 bases) insertions/deletions (Large Indels), copy number variants (CNVs), and gene fusions. The assay utilizes the Thermo Fisher Scientific Oncomine® Comprehensive Assay v3.0 (OCAv3), a next-generation sequencing (NGS) assay that utilizes a multiplex polymerase chain reaction (PCR) with DNA and RNA extracted from formalin-fixed tissue for sequencing on the Ion S5 XL platform and analyzed by the current version of Torrent Suite Software and Ion Reporter. The OCAv3 NGS Assay currently can reliably

Shahanawaz Jiwani. MD. PhD. Laboratory Director | CLIA ID 21D2097127

Disclaimer: The data presented here is from a curated knowledgebase of publicly available information, but may not be exhaustive. The data version is 2021.01(005).

6. Assay Information

The biomarker test looks for three types of biomarkers:

- Single Nucleotide Variants and Indel which are variations of a gene
- Copy Number Variants which is the number of times a gene is repeated
- Gene fusions when two separate genes combine together. Get more information on the genetics of cancer.